Corporate Governance

Leadership Team


Joshua H. Bilenker, M.D.
Joshua H. Bilenker, M.D.
Chief Executive Officer

Dr. Joshua H. Bilenker, M.D., founder of Loxo Oncology, serves as President and Chief Executive Officer, and sits on the board of directors.

Previously, Dr. Bilenker was a Partner at Aisling Capital, a multi-strategy healthcare investment firm based in NY, where he remains an Operating Partner.

From 2004-2006, Dr. Bilenker was a Medical Officer at the U.S. FDA in the Office of Oncology.

Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree from Princeton University.

Jacob S. Van Naarden
Jacob S. Van Naarden
Chief Business Officer

Jacob S. Van Naarden serves as Chief Business Officer. In his previous roles, Mr. Van Naarden served in various biotechnology investing, operating, and advisory capacities.

Previously, Mr. Van Naarden served as a public equity biotechnology analyst at HealthCor Management, a multi-billion-dollar healthcare-dedicated investment firm based in NYC. Prior to HealthCor, Mr. Van Naarden was an Associate at Aisling Capital, a multi-strategy healthcare investment firm based in NY. Mr. Van Naarden started his career in the Healthcare Group of the Investment Banking Division at Goldman Sachs.

Mr. Van Naarden received his A.B. degree in molecular biology from Princeton University, graduating magna cum laude and Phi Beta Kappa.

Jennifer Burstein, C.P.A.
Jennifer Burstein, C.P.A.
Senior VP, Finance

Jennifer Burstein, C.P.A., serves as Senior Vice President of Finance.

Prior to Loxo Oncology, Ms. Burstein served as Vice President of Finance at Acorda Therapeutics, Inc., a public biotechnology company, from July 2010 until April 2015, where she held several positions of increasing responsibility in Finance from 2006 until being appointed Vice President of Finance.

Prior to joining Acorda, from 2002 to 2006, she was with Eyetech Pharmaceuticals, Inc., a public biotechnology company, which is currently a subsidiary of Valeant Pharmaceuticals International, Inc., where she held several positions of increasing responsibility in Finance until being promoted to Senior Director, Accounting. Before Eyetech, Ms. Burstein worked in the Finance departments at several companies and in public accounting.

Ms. Burstein received her B.S. in Business Administration and MBA in Accounting from the State University of New York at Buffalo and has a C.P.A. license in New York.

Nisha Nanda, Ph.D.
Nisha Nanda, Ph.D.
Senior VP, Development Strategy

Dr. Nanda serves as Senior Vice President of Development Strategy. Dr. Nanda has had increasing roles of responsibility in both clinical and pre-clinical development. Most recently Dr. Nanda worked on the clinical development of carfilzomib (Kyprolis) and the approval of omacetaxine (Synribo).

Dr. Nanda’s career in drug development has included roles at Onyx, ChemGenex, Portola, Millennium and Cor.

Dr. Nanda has a BSc Hons in Biochemistry and Molecular Genetics from UNSW, Sydney, Australia and a Ph.D. in Biochemistry and Molecular Genetics from UNSW and the Victor Chang Cardiac Research Institute, Sydney, Australia.

Sara Slifka
Sara Slifka
VP, Business Operations & Program Management

Sara Slifka serves as Vice President of Business Operations and Program Management. Previously, Ms. Slifka was a Vice President in Equity Research at Morgan Stanley covering the biotech sector.

In her prior role, Ms. Slifka analyzed small- and large-cap biotechnology companies from a financial, clinical, regulatory and commercial perspective.

Ms. Slifka received her A.B. degree from Princeton University.

Michael Rothenberg, M.D., Ph.D.
Michael Rothenberg, M.D., Ph.D.
VP, Research and Development

Dr. S. Michael Rothenberg, M.D., Ph.D., serves as Vice President of Research and Development.

Previously, Dr. Rothenberg was a medical oncologist and cancer researcher at Massachusetts General Hospital.

Dr. Rothenberg trained at Massachusetts General Hospital in internal medicine and at the Massachusetts General Hospital Cancer Center and the Dana Farber Cancer Institute in medical oncology, earning board certification in these specialties. He received his M.D. and Ph.D. degrees from the Stanford University School of Medicine, and his B.A. degree in Chemistry from Yale University.

Christopher Pierce, MBA
Christopher Pierce, MBA
VP, Commercial

Christopher Pierce, MBA, serves as Vice President of Commercial.

Previously, Mr. Pierce worked at Pfizer Oncology from 2007 to 2017 in roles of increasing commercial responsibility, including the launch or in-line management of various oncology therapeutics such as Xalkori (crizotinib), Sutent (sunitinib), Inlyta (axitinib), Bosulif (bosutinib), Mylotarg, (gemtuzumab ozogamicin), and Besponsa (inotuzumab ozogamicin).

From 2004 to 2006, Mr. Pierce worked at Millennium Pharmaceuticals managing market analytics for Velcade (bortezomib). Before Millennium, Mr. Pierce was a management strategy consultant at L.E.K. Consulting within its life sciences practice.

Mr. Pierce received his A.B. degree in biochemical sciences from Harvard College, graduating magna cum laude. He received his MBA from the Harvard Business School with high distinction, where he was named a George F. Baker Scholar.

Jennifer L. Kronick
Jennifer L. Kronick
VP, Human Resources

Jennifer L. Kronick serves as Vice President, Human Resources.

Previously, Ms. Kronick was Senior Assistant General Counsel at Purdue Pharma L.P., where her work included an international assignment in Basel, Switzerland supporting emerging markets. Previously, she worked as a labor and employment law associate at Morgan Lewis in New York and as a Trial Preparation Assistant in the New York County District Attorney’s Office Sex Crimes Prosecution Unit.

Ms. Kronick received her B.A. degree with college honors from Washington University in St. Louis and her law degree from Columbia Law School, where she was a Harlan Fiske Stone Scholar. She is admitted to practice in Connecticut and New York.

Deborah Morosini, M.D., M.S.W.
Deborah Morosini, M.D., M.S.W.
VP, Clinical Affairs and Patient Engagement

Dr. Deborah Morosini, M.D., M.S.W., serves as Vice President of Clinical Affairs and Patient Engagement.

Previously, Dr. Morosini was a VP at Foundation Medicine, a cancer genomics and molecular information company in Cambridge, MA. From 2007-2012, Dr. Morosini led the molecular pathology group at AstraZeneca Pharmaceuticals.

She is a seasoned patient advocate, serving on multiple national non-profit boards.

Dr. Morosini trained at Boston University School of Medicine in anatomic and clinical pathology, where she served as chief resident. She received her M.D. from Boston University School of Medicine, her Masters in Social Work from New York University and her B.A. in English from Mount Holyoke College.

Sunitha Ramamurthy, Esq.
Sunitha Ramamurthy, Esq.
Head of Compliance

Sunitha Ramamurthy serves as Head of Compliance, which includes oversight of privacy matters.

Previously, as Executive Director at Boehringer Ingelheim Pharmaceuticals Inc., Ms. Ramamurthy oversaw the Office of Ethics & Compliance in the U.S., which included healthcare, Anti-Bribery and Anti-Corruption and Transparency & Disclosure compliance areas.

Ms. Ramamurthy also worked at Eisai Inc., as Senior Director, Commercial Compliance and as a litigator for ten years representing healthcare clients.

Ms. Ramamurthy earned a B.S. from S.I. Newhouse School of Public Communications, Syracuse University, and graduated cum laude from Seton Hall School of Law with a J.D. in 1996. She is admitted to practice in New York and New Jersey.

Nora Ku, M.D.
Nora Ku, M.D.
Executive Medical Director

Dr. Nora Ku, M.D., serves as Executive Medical Director for Loxo Oncology.

Her career in academic and community practice included active involvement in clinical research as a clinical investigator. Prior to joining Loxo Oncology Dr. Ku worked with a specialty consulting group supporting projects facilitating drug development by large and small pharmaceutical company clients.

Dr. Ku is a graduate of the UCLA School of Medicine. She completed her residency in Internal Medicine at UT Southwestern Medical Center and returned to UCLA to complete a combined fellowship in Hematology and Oncology. She is board certified in Internal Medicine and Medical Oncology.

Katie Cairati
Katie Cairati
Executive Director, Regulatory Affairs

Katie Cairati serves as Executive Director, Global Regulatory Affairs. Ms. Cairati’s career spans many aspects of drug development including regulatory affairs, clinical development, data management and manufacturing.

Previously Ms. Cairati has held increasing roles of responsibility at Genentech, Pharmacyclics and ChemGenex in addition to establishing her own consulting firm, Cairati Consulting Inc.

Ms. Cairati received her M.S. degree from University of California, Davis.

Michael Cox, Pharm.D.
Michael Cox, Pharm.D.
Senior Director, Clinical Development and Medical Affairs

Dr. Michael Cox, Pharm.D., serves as Senior Director, Clinical Development and Medical Affairs. Dr. Cox has been involved in the product launches and life cycle management of numerous oncology products including radium-223 (Xofigo®), regorafenib (Stivarga®), sorafenib (Nexavar®) cetuximab (ERBITUX®), denosumab (XGEVA®) and darbepoetin alfa (Aranesp®).

Dr. Cox joined Loxo Oncology from Bayer Consumer Care AG, Basel, Switzerland where he served as Medical Affairs Early Pipeline Lead, Oncology for Region Europe/Canada and Emerging Markets. Prior to Bayer, he held global medical affairs positions at Merck KGaA, Darmstadt, Germany and Amgen, Inc., Thousand Oaks, California.

Dr. Cox received his Pharm.D. from Ohio Northern University and a MHSc in Clinical Research from Duke University’s School of Medicine. Dr. Cox completed pharmacy practice residencies at Mission Hospitals in Asheville, North Carolina and the University of Pittsburgh Cancer Institute – University of Pittsburgh Medical Cancer, Pittsburgh, Pennsylvania. He completed a medical oncology/clinical drug development fellowship in the Clinical Pharmacology Section, Center for Cancer Research at the National Cancer Institute, Bethesda, Maryland. He is a Board Certified Oncology Pharmacist.

Brian Tuch, Ph.D.
Brian Tuch, Ph.D.
Senior Director, Translational Medicine

Dr. Brian Tuch serves as Senior Director of Translational Medicine, leading preclinical biomarker research and clinical diagnostic assay development.

Dr. Tuch has previously contributed to the discovery and development of drugs and diagnostic technologies at companies including Onyx, Amgen and Life Technologies. At Onyx and Amgen, he built groups applying advanced genomic technologies, such as next generation sequencing (NGS), towards the discovery of biomarkers and drug targets.

Dr. Tuch received a Ph.D. in Bioinformatics from University of California San Francisco, where he combined novel bench and computational methods to understand basic principles of gene regulation and their relevance to human disease. Dr. Tuch received an ScB in Computational Biology with Honors from Brown University.

Board of Directors


Joshua H. Bilenker, M.D.
Chief Executive Officer

Dr. Joshua H. Bilenker, M.D., founder of Loxo Oncology, serves as President and Chief Executive Officer, and sits on the board of directors.

Previously, Dr. Bilenker was a Partner at Aisling Capital, a multi-strategy healthcare investment firm based in NY, where he remains an Operating Partner.

From 2004-2006, Dr. Bilenker was a Medical Officer at the U.S. FDA in the Office of Oncology.

Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree from Princeton University.

Steve Elms

Mr. Steve Elms has served on the board of directors since July 2013.

Mr. Elms is currently a Managing Partner at Aisling Capital, a leading private equity fund investing in life science companies, and serves on the board of a number of public and private life sciences companies.

Previously, Mr. Elms was a senior member of the Life Sciences Investment Banking Group of Hambrecht & Quist and was involved in over 60 financing and M&A transactions, which helped clients raise in excess of $3.3 billion in capital. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories.

Mr. Elms received an MBA from the Kellogg Graduate School of Management at Northwestern University, and a B.A. in Human Biology from Stanford University.

Keith T. Flaherty, M.D.
Director, and Chair of the SAB

Dr. Keith T. Flaherty has served as SAB Chair since company inception, and sits on the board of directors.

Dr. Flaherty is currently Director of Clinical Research and the Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, and is a Professor of Medicine at Harvard Medical School.

Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital, and in medical oncology at the University of Pennsylvania, earning board certification in these specialties.

He received his M.D. from The Johns Hopkins School of Medicine and his B.S. degree from Yale University.

Avi Z. Naider

Mr. Avi Z. Naider has served on the board of directors since September 2013.

Mr. Naider is currently Chairman and CEO of ACES Risk Management Corp.

Mr. Naider is a successful entrepreneur who has founded and managed companies in various sectors, including internet advertising and mortgage industry software. He previously worked in private equity and for the Boston Consulting Group.

Mr. Naider received his A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University, where he graduated Phi Beta Kappa.

Lori A. Kunkel, M.D.

Dr. Lori A. Kunkel has served on the board of directors since October 2014.

Dr. Kunkel served as Acting Chief Medical Officer for Loxo Oncology from October 2013 to October 2014.

As principal of LAK 505, LLC, she is a clinical/regulatory strategic advisor to public and private biotech companies in the San Francisco, San Diego, New York and Boston areas. She currently serves on the board of directors of Curis, Inc, Tocagen and Maverick Therapeutics and is a clinical advisor to Amphvena, Atreca and Verastem. Dr. Kunkel served as Chief Medical Officer at Pharmacyclics, Inc. leading integrated clinical development highlighted by the approval of IMBRUVICA. She has also served as Chief Medical Officer at Proteolix Inc. (acquired by Onyx), Syndax, and ACT Biotech.

Prior to joining the international biotechnology industry in 1995, Dr. Kunkel spent ten years in academic/clinical medicine and served as a faculty member in the Division of Hematology/Oncology’s Bone Marrow Transplant Unit at University of California, Los Angeles.

She trained in internal medicine at Baylor College of Medicine, hematology at USC and oncology at UCLA, earning board certifications in these specialties.

Alan Fuhrman

Alan Fuhrman has served on our board of directors since January 2015.

Mr. Fuhrman currently serves as CFO of Amplyx Pharmaceuticals a drug development company focused on life-threatening infections.

Prior to joining Amplyx, he served as CFO of publicly-traded Mirna Therapeutics, a clinical-stage microRNA company that merged with Synlogic in August 2017. Prior to that, Mr. Fuhrman was CFO of Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. He has also served as the CFO at Naviscan, a privately held medical imaging company, and Sonus Pharmaceuticals, a publicly traded oncology-focused biotechnology company. Earlier in his career, Mr. Fuhrman practiced as a certified public accountant with Coopers & Lybrand.

Mr. Fuhrman received a B.S. in both Business Administration and Agricultural Economics from Montana State University.

Tim Mayleben

Tim Mayleben has served on the board of directors since July 2015.

Mr. Mayleben is currently President and Chief Executive Officer at Esperion Therapeutics and has been a member of the board of directors since 2010.

Mr. Mayleben is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaleo Pharma, Marinus Pharmaceuticals and the Wolverine Venture Fund.

Mr. Mayleben earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.B.A. from the University of Michigan, Ross School of Business.

Steve D. Harr, M.D.

Dr. Steve D. Harr joined the board of directors in November 2016.

Dr. Harr is currently the chief financial officer and head of corporate development at Juno Therapeutics, a biopharmaceutical company developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies.

Previously, Dr. Harr was managing director and head of biotechnology investment banking at Morgan Stanley. Prior to his investment banking role at Morgan Stanley, Dr. Harr was Morgan Stanley’s lead biotech research analyst and co-head of Global Healthcare Research.

Dr. Harr received a B.A. in economics from College of the Holy Cross and an M.D. from The Johns Hopkins University School of Medicine. Dr. Harr was a resident in internal medicine at the University of California, San Francisco.

Governance Documents


The Board of Directors of Loxo Oncology, Inc. (the “Company”) sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business.

To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Committee Composition


Audit
Compensation
Compliance
Committee
Nominating & Governance
Joshua H. Bilenker, M.D.
Avi Z. Naider
Steve Elms
Keith T. Flaherty, M.D.
Lori A. Kunkel, M.D.
Alan Fuhrman
Tim Mayleben
Steve D. Harr, M.D.
 = Chair
 = Member

Contact the Board


You can contact Loxo Oncology, Inc.'s Board of Directors to provide comments, to report concerns, or to ask a question, at the following address.

Corporate Secretary
Loxo Oncology, Inc.
281 Tresser Blvd, 9th Floor
Stamford, CT 06901 

United States

You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier, or other interested party.

Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, the Loxo Oncology, Inc. board of directors has requested that certain items which are unrelated to the duties and responsibilities of the board should be excluded, such as:

  • Product complaints
  • Product inquiries
  • New product suggestions
  • Resumes and other forms of job inquiries
  • Surveys
  • Business solicitations or advertisements

In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request.

Email Alerts

Receive alerts for Press Releases, Events & Presentations, SEC Filings & EOD Stock Quote

Sign up